Cogent Biosciences Inc
Suletud
32.7 -4.36
Ülevaade
Aktsiahinna muutus
24h
Min
32.34
Max
34.2
Sissetulek | 5.1M -97M |
|---|---|
Aktsiakasum | -0.53 |
Töötajad | 258 |
EBITDA | 6.2M -102M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +51.94% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | -447M 5.8B |
|---|---|
Eelmine avamishind | 37.06 |
Eelmine sulgemishind | 32.7 |
Tehniline skoor
By Trading Central
Kindlus
Bearish Evidence
Cogent Biosciences Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Cogent Biosciences Inc Prognoos
Hinnasiht
By TipRanks
51.94% tõus
12 kuu keskmine prognoos
Keskmine 52.1 USD 51.94%
Kõrge 64 USD
Madal 35 USD
Põhineb 11 Wall Streeti analüütiku instrumendi Cogent Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Cogent Biosciences Inc
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
